{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:03:31Z","timestamp":1771639411154,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10787-025-02105-1","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T15:09:30Z","timestamp":1768576170000},"page":"1277-1284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical 10% sulfasalazine ointment attenuates imiquimod-induced psoriasiform inflammation in mice compared with clobetasol"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8675-1393","authenticated-orcid":false,"given":"Mohammed Abdul Muttalib Abdul","family":"Bari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"10","key":"2105_CR1","first-page":"767","volume":"309","author":"WH Boehncke","year":"2017","unstructured":"Boehncke WH, Sch\u00f6n MP (2017) Mouse models of psoriasis: tools for specific targeting of disease mechanisms. Arch Dermatol Res 309(10):767\u2013776","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"2105_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","volume":"35","author":"Y Cai","year":"2011","unstructured":"Cai Y, Fleming C, Yan J (2011) Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation. Immunity 35(4):596\u2013610","journal-title":"Immunity"},{"issue":"4","key":"2105_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4103\/2229-5178.142483","volume":"5","author":"A Coondoo","year":"2014","unstructured":"Coondoo A, Phiske M, Verma S, Lahiri K (2014) Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J 5(4):416\u2013425","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"2105_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaci.2015.10.046","volume":"138","author":"P Di Meglio","year":"2016","unstructured":"Di Meglio P, Villanova F, Nestle FO (2016) Targeting CD8+ T cells prevents psoriasis development. J Allergy Clin Immunol 138(1):274\u2013276","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2105_CR5","first-page":"425","volume":"18","author":"SR Feldman","year":"2017","unstructured":"Feldman SR, Zhao Y, Shi L, Tran MH (2017) Combination therapies in psoriasis management. Am J Clin Dermatol 18(4):425\u2013432","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2105_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","volume":"69","author":"AM Goldminz","year":"2013","unstructured":"Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF (2013) NF-\u03baB: an essential transcription factor in psoriasis. J Dermatol Sci 69(2):89\u201394","journal-title":"J Dermatol Sci"},{"issue":"9583","key":"2105_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370(9583):263\u2013271","journal-title":"Lancet"},{"key":"2105_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","volume":"48","author":"E Guttman-Yassky","year":"2018","unstructured":"Guttman-Yassky E, Krueger JG (2018) Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol 48:68\u201373","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2105_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jid.2017.10.013","volume":"138","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Chan TC, Krueger JG (2018) Research techniques made simple: mouse models of psoriasis. J Invest Dermatol 138(1):e1\u2013e8","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2105_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","volume":"130","author":"JG Krueger","year":"2012","unstructured":"Krueger JG, Fretzin S, Su\u00e1rez-Fari\u00f1as M et al (2012) IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130(1):145\u2013154","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2105_CR11","first-page":"971","volume":"13","author":"M Lebwohl","year":"2014","unstructured":"Lebwohl M, Bachelez H, Barker J et al (2014) Psoriasis treatment: current and emerging directed therapies. Lancet Rev Drug Discov 13(12):971\u2013982","journal-title":"Lancet Rev Drug Discov"},{"issue":"3","key":"2105_CR12","first-page":"234","volume":"31","author":"CH Lee","year":"2020","unstructured":"Lee CH, Wu SB, Hong CH, Yu HS (2020) Restoration of skin architecture in psoriasis treatment. J Dermatol Treat 31(3):234\u2013240","journal-title":"J Dermatol Treat"},{"key":"2105_CR13","first-page":"41","volume":"439","author":"T Mabuchi","year":"2016","unstructured":"Mabuchi T, Singh TP, Takekoshi T et al (2016) Standardized scoring systems for evaluating psoriasis-like skin inflammation. J Immunol Methods 439:41\u201347","journal-title":"J Immunol Methods"},{"issue":"1","key":"2105_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA et al (2011) Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 65(1):137\u2013174","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2105_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J (2009) Mechanisms of disease: psoriasis. N Engl J Med 361(5):496\u2013509","journal-title":"N Engl J Med"},{"issue":"11","key":"2105_CR16","first-page":"1","volume":"2","author":"K Reich","year":"2012","unstructured":"Reich K, Rich P, Matheson RT et al (2012) Comparative effectiveness of biologic agents for the treatment of psoriasis. Dermatol Ther 2(11):1\u201316","journal-title":"Dermatol Ther"},{"issue":"2","key":"2105_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/bjd\/ljac057","volume":"184","author":"K Reich","year":"2021","unstructured":"Reich K, Puig L, Lebwohl M, Griffiths CEM, Barker JNWN (2021) Efficacy and safety of biologics in the treatment of moderate to severe psoriasis. Br J Dermatol 184(2):208\u2013220","journal-title":"Br J Dermatol"},{"issue":"5","key":"2105_CR18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","volume":"130","author":"MP Sch\u00f6n","year":"2010","unstructured":"Sch\u00f6n MP, Erpenbeck L (2010) The IL-23\/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 130(5):1373\u20131379","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2105_CR19","first-page":"456","volume":"180","author":"J Smith","year":"2019","unstructured":"Smith J, Thomas R, Li W, Brown D (2019) Efficacy of a novel biologic agent in psoriasis: a randomized controlled trial. Br J Dermatol 180(2):456\u2013465","journal-title":"Br J Dermatol"},{"issue":"9","key":"2105_CR20","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"L van der Fits","year":"2009","unstructured":"van der Fits L, Mourits S, Voerman JSA et al (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol 182(9):5836\u20135845","journal-title":"J Immunol"},{"issue":"12","key":"2105_CR21","first-page":"2994","volume":"135","author":"H Vinter","year":"2015","unstructured":"Vinter H, Iversen L, Steiniche T et al (2015) IMQ-induced psoriasis-like skin inflammation in mouse models: protocol standardization and scoring systems. J Invest Dermatol 135(12):2994\u20133004","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2105_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI992","volume":"101","author":"C Wahl","year":"1998","unstructured":"Wahl C, Liptay S, Adler G, Schmid RM (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101(5):1163\u20131174","journal-title":"J Clin Invest"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02105-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02105-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02105-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:12:46Z","timestamp":1771636366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02105-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02105-1","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was carried out in accordance with all the norms and standards specified by the code of ethics at Al-Nahrain University\u2019s Biotechnology Research Center. All animal procedures used in this research were reviewed and approved by the Institutional Animal Care and Use Committee. The pain and distress of animals were minimized, and humane care was provided. The present research was conducted under the guidance of ethical standards set by the Biotechnology Research Center, at Al-Nahrain University. All animal experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study does not involve human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal participants"}}]}}